Abivax (ABVX) Other Operating Expenses (2024 - 2026)

Abivax's Other Operating Expenses history runs 3 years deep, the most recent figure standing at -$2.0 million for Q1 2026.

• On a quarterly basis, Other Operating Expenses fell 126.35% year-over-year to -$2.0 million in Q1 2026; TTM through Mar 2026 was $576.5 million, a 47.43% increase from a year earlier, with the FY2025 full-year figure at $577.5 million, up 46.25% from the prior year.
• Other Operating Expenses eased to -$2.0 million in Q1 2026 per ABVX's latest filing, from $581.4 million in the prior quarter.
• Across five years, Other Operating Expenses topped out at $581.4 million in Q4 2025 and bottomed at -$2.4 million in Q2 2024.
• The 3-year median for Other Operating Expenses is -$936781.2 (2024), against an average of $107.3 million.
• Biggest YoY gain for Other Operating Expenses was 68.53% in 2025; the steepest drop was 129.5% in 2025.
• Year by year, Other Operating Expenses stood at $395.3 million in 2024, then soared by 47.09% to $581.4 million in 2025, then slumped by 100.35% to -$2.0 million in 2026.
• Per Business Quant, the three latest ABVX Other Operating Expenses figures stand at -$2.0 million (Q1 2026), $581.4 million (Q4 2025), and -$2.1 million (Q3 2025).